| HOME >> MEDICINE >> TECHNOLOGY |
In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc.
Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals, Inc. Regulus Therapeutics is a trademark of Regulus Therapeutics Inc.ISIS PHARMACEUTICALS, INC.SELECTED FINANCIAL INFORMATIONCondensed Consolidated Statements of Operations(In Thousands, Except Per Share Data)Three months ended,Nine months ended,September 30,September 30,20102009(1)20102009(1)Revenue:(unaudited)(unaudited)Research and development revenue under collaborative agreements$27,785$25,962$77,484$86,415Licensing and royalty revenue8398094,5692,924Total revenue28,62426,77182,05389,339Expenses:Research and development 34,71633,832105,82794,519General and administrative 2,8553,3358,72410,685Total operating expenses37,57137,167114,551105,204Loss from operations(8,947)(10,396)(32,498)(15,865)Other income (expense):Equity in net loss of Regulus Therapeutics Inc.(930)-(6,358)-Investment income7761,4302,5905,241Interest expense(3,338)(3,185)(9,835)(9,421)Gain (loss) on investments, net(15)123(1,162)2,794Loss from continuing operations, before income tax expense (12,454)(12,028)(47,263)(17,251)Income tax expense-(724)(2)(873)Net loss from continuing operations(12,454)(12,752)(47,265)(18,124)Discontinued operations:Loss from discontinued operations---(29)Gain on sale of Ibis Biosciences, Inc., net of tax-34-187,153Net income from discontinued operations, net
'/>"/>
| SOURCE Isis Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved |